News | May 04, 2024
Ajanta Pharma posts Q4 FY24 consolidated PAT at Rs. 202.72 Cr
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
New solvent-free micronization technology expanded at the Darmstadt site in Germany
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Subscribe To Our Newsletter & Stay Updated
